Japan's Drugstore Lobby Pushes to Loosen Loxoprofen Sales Restrictions
JACDS is mobilising its member companies to back a public consultation that could reclassify a widely-used NSAID from a pharmacist-only product to one any registered seller may handle.
The Japan Association of Chain Drug Stores (JACDS) has circulated an internal notice urging member companies to participate in a Ministry of Health, Labour and Welfare public consultation on whether loxoprofen — currently classified as a Category 1 OTC medicine, requiring a qualified pharmacist to be present at the point of sale — should be reclassified as a Designated Category 2 medicine. That lower classification would permit registered sellers (登録販売者), who are far more numerous across the drugstore estate, to handle transactions without a pharmacist on the shop floor.
According to the association, this is not a new position. JACDS said it has lobbied the ministry repeatedly and with considerable force over time for exactly this reclassification. The public consultation now under way represents, in effect, the regulatory process catching up with sustained industry advocacy — a relatively rare sequence in Japanese pharmaceutical administration.
The notice requests that member firms submit responses both as corporate entities and by encouraging individual employees — pharmacists, registered sellers, and shop-floor staff — as well as their family members and the general public, to submit personal opinions. The association also provided sample comment text as a reference, while asking participants to frame submissions in their own words. The approach signals a deliberate effort to demonstrate breadth of public support rather than simply a concentrated industry position.
What This Means for the Retail Floor
For chain drugstore operators, the commercial stakes are meaningful. Category 1 products carry staffing constraints that limit where and when they can be sold; reclassification would expand effective selling hours and reduce dependency on pharmacist scheduling. Loxoprofen is among the best-recognised pain-relief brands in Japan, and its accessibility at the till — rather than behind a consultation counter — would directly affect basket economics and footfall conversion for the segment.
What to watch: the outcome of the public consultation and any subsequent ministerial response will be the key signal. Observers should also monitor whether the volume and composition of submitted comments — individual versus corporate — influences how the ministry frames its eventual decision. If reclassification proceeds, expect other Category 1 products to face renewed lobbying pressure for similar treatment.